ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study

• The study tested Pelareorep together with RAS-targeting drugs in a solid tumor model.
• Oncolytics plans to expand testing in pancreatic ductal adenocarcinoma and colorectal cancer models.
• Full results are expected to be presented in the fall or winter of 2026, the company said.

Shares of Oncolytics Biotech (ONCY) surged more than 12% on Monday as investors welcomed promising preclinical data showing its experimental immunotherapy delivered stronger anti-tumor effects in a combination therapy, strengthening hopes for future treatments in pancreatic and colorectal cancers.

ONCY shares have been on a strong rally, rising for six straight sessions and gaining nearly 50% over that period.

The stock is also looking to break a key near-term resistance level near the $1.19 mark.

Source: TradingView

ONCY’s Lead Drug Shows Promise

The study tested Pelareorep together with RAS-targeting drugs in a solid tumor model. RAS-targeting drugs are treatments that block abnormal proteins that enable cancer cells to spread.

Pelareorep is designed to stimulate the immune system’s response against cancer by increasing inflammatory signaling and promoting the growth of immune cells within tumors.

ONCY Set To Expand Testing To Pancreatic, Colorectal Cancer

Based on the findings, Oncolytics plans to expand testing in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models. Future studies will examine immune activation, durability of tumor response, and the potential to delay treatment resistance.

“Importantly, we believe this strategy may ultimately represent a potentially important area for further investigation in pancreatic cancer, where nearly all tumors harbor RAS pathway alterations and where patients continue to face extremely limited treatment options,” said CEO Jared Kelly.

Full results from the initial preclinical studies are expected to be presented in the fall or winter of 2026, the company added.

What Is Retail’s View On ONCY?

Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes.

One user noted the formation of higher lows on the weekly chart.

ONCY shares have gained more than 22% so far this year compared to the SPDR S&P Biotech ETF’s (XBI) 7% gains.

Read also: EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business

For updates and corrections, email newsroom[at]stocktwits[dot]com.